Amneal Pharmaceuticals, Inc. (AMRX) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Amneal Pharmaceuticals, Inc. (AMRX)
A forensic read on Amneal Pharmaceuticals, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
4.0
Distress distance
Clean
Earnings quality
3
Forensic signals
38.0
P / E (ttm)
$6.7B
Market cap
8.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Amneal Pharmaceuticals, Inc. earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 4.0, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
14.1%
FY2025
Return on invested capital.Return on invested capital is 14.1% in the latest fiscal year and rising across FY2023–FY2025 from 6.3%. After-tax operating profit was $161M in FY2023 and $355M in FY2025, with operating income at 8.5% of revenue in FY2023, 8.9% in FY2024 and 13.1% in FY2025. The capital base behind it barely moved across FY2023–FY2025 ($2.6B to $2.5B, -2%), so there has been little new capital for that return to be earned on. FY2023's operating profit carried a $31M asset write-down and a $2M restructuring charge that alone took about 1.0 points off that year's return, so about 1.0 of the 7.8-point rise across FY2023–FY2025 is that charge leaving the base year rather than the capital earning more.
n/m (stock split)
FY2023–FY2025
Share count (stock split).Diluted share count changed +84% over the last 2 years to FY2025, but that includes a large one-time change around FY2024 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +35.8%/yr figure isn't a real buyback/dilution read here.
1.1% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 1.1% of revenue and 12% of free cash flow in FY2025 — about $0.10 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 5.1% a year, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$3.02B
Revenue Growth YoY+8.0%
Revenue CAGR (2yr)+12.3%
Net Margin2.4%
Free Cash Flow$269.9M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Amneal Pharmaceuticals, Inc.'s actual 10-K/10-Q/8-K filings?